Exact sciences corporation stock.

MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, ... Represents stock-based compensation expense and 401(k) match expense as the …Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress. PR Newswire Oct 20, 2023 10:08pm.Exact Sciences Corp. completed the acquisition of Thrive Earlier Detection Corp. in a cash and stock deal valued at up to $2.15 billion. Under the previously disclosed terms of the deal, Thrive's shareholders were to receive $1.7 billion at closing, consisting of 65% in Exact Sciences common stock and 35% in cash. Thrive would also be eligible ...Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.Stock Price Forecast ... The 17 analysts offering 12-month price forecasts for Exact Sciences Corp have a median target of 92.00, with a high estimate of 120.00 ...

Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact information

Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Nov 14, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ... EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level …29-Jul-2019 ... Exact Sciences Corporation (EXAS) shares fell more than 7% during Monday's session after the company announced a $2.8 billion deal to ...Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...

A high-level overview of Exact Sciences Corporation (EXAS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment …

Dec 1, 2023 · About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days.. Most of that value climb came yesterday, with the ...Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...MADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...Stock Quote. Change: +0.09 ( +0.14%) Volume: 1,381,347. Previous Close: 64.97. Open: 66.02. NASDAQ: EXAS. 65.06. November 29, 2023 04:00 PM. Day High: 67.98.Achieving some impressive results. Exact Sciences has already done well in growing its business. Sales of $1.8 billion in 2021 were double what the company generated in 2019 ($876 million).Jul 10, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ... Stock Information · Financial Information · SEC Filings · Quarterly Results · Analyst Coverage ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI ...

As of November 29, 2023, Exact Sciences Corp had a $11.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $79.5 million. Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price …

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsIndian Oil Corporation Ltd., Tata Motors Ltd., Reliance Industries Ltd. and the State Bank of India are four of the biggest joint stock companies of India. A joint stock company is simply a business entity in which stakes are owned jointly ...Apr 19, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, Exact ... MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Find the latest Exact Sciences Corporation (EXAS ... Feb 23, 2023 · MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...

The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...

Stocks United States EXAS Overview Stock Screener Earnings Calendar Sectors Nasdaq | EXAS U.S.: Nasdaq Exact Sciences Corp. Watch NEW Set a price target alert Premarket Last Updated: Nov...

View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress. PR Newswire Oct 20, 2023 10:08pm.View live Exact Sciences Corporation chart to track its stock's price action. Find market predictions, EXAS financials and market news.Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ...EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 52 Item 2. Properties 52 Item 3. Legal Proceedings 53 Item 4. Mine Safety Disclosures 53 Part II Item 5.MADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.Exact Sciences announces third quarter 2021 results. MADISON, Wis., Nov. 2, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting ...Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com. About Exact Sciences Corp.Stock EXAS November 21, 2023 NASDAQ 20 minutes delay ... At Exact Sciences, our mission is to eradicate cancer and the suffering it causes — through tests that help prevent it, detect it earlier ...

EXAS Exact Sciences Corp. Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ; Owners. Institutional Owners Retail Ownership Net Long/ ...23-Feb-2023 ... Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP). The 2030 ... The offer and sale of the 2030 Notes and any shares of common stock ...Business intelligence is what S&P ratings are all about. This global corporation provides credit ratings on investments, including bonds and the stock market. Before you can understand what a good rating is, it helps to understand the origi...Nov 17, 2023 · Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq. Instagram:https://instagram. best day trading servicebrystol myers squibb stockapple stock graphwhat is the best dental insurance for dentures Business intelligence is what S&P ratings are all about. This global corporation provides credit ratings on investments, including bonds and the stock market. Before you can understand what a good rating is, it helps to understand the origi...15-May-2017 ... One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known ... 5 year us treasuryoptions to buy today Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. yeti stock value EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19 Item 1B. Unresolved Staff Comments 52 Item 2. Properties 52 Item 3. Legal Proceedings 53 Item 4. Mine Safety Disclosures 53 Part II Item 5. May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. Exact Sciences Corp. lowest stock price was $40.73 and its highest was $100.77 in the past 12 months. What is Exact Sciences Corp.’s market cap? ... Exact Sciences Corp. released its earnings results on Nov 01, 2023. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.471 by $0.471. ...